PALVELLA THERAPEUTICS INC (PVLA) Stock Fundamental Analysis

NASDAQ:PVLA • US6979471090

135.02 USD
-13.32 (-8.98%)
At close: Feb 27, 2026
135.02 USD
0 (0%)
After Hours: 2/27/2026, 9:28:40 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall PVLA gets a fundamental rating of 3 out of 10. We evaluated PVLA against 520 industry peers in the Biotechnology industry. PVLA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PVLA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year PVLA has reported negative net income.
  • PVLA had a negative operating cash flow in the past year.
  • In the past 5 years PVLA always reported negative net income.
  • PVLA had a negative operating cash flow in each of the past 5 years.
PVLA Yearly Net Income VS EBIT VS OCF VS FCFPVLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -52.39%, PVLA perfoms like the industry average, outperforming 47.89% of the companies in the same industry.
  • With a Return On Equity value of -90.66%, PVLA perfoms like the industry average, outperforming 47.89% of the companies in the same industry.
Industry RankSector Rank
ROA -52.39%
ROE -90.66%
ROIC N/A
ROA(3y)-39.19%
ROA(5y)-36.56%
ROE(3y)-79.34%
ROE(5y)-89.63%
ROIC(3y)N/A
ROIC(5y)N/A
PVLA Yearly ROA, ROE, ROICPVLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PVLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PVLA Yearly Profit, Operating, Gross MarginsPVLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • PVLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PVLA has been increased compared to 1 year ago.
  • Compared to 5 years ago, PVLA has more shares outstanding
  • PVLA has a worse debt/assets ratio than last year.
PVLA Yearly Shares OutstandingPVLA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PVLA Yearly Total Debt VS Total AssetsPVLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 30.98 indicates that PVLA is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of PVLA (30.98) is better than 92.34% of its industry peers.
  • PVLA has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.41, PVLA is doing worse than 69.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 30.98
ROIC/WACCN/A
WACC8.61%
PVLA Yearly LT Debt VS Equity VS FCFPVLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

  • A Current Ratio of 6.49 indicates that PVLA has no problem at all paying its short term obligations.
  • The Current ratio of PVLA (6.49) is better than 65.71% of its industry peers.
  • PVLA has a Quick Ratio of 6.49. This indicates that PVLA is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 6.49, PVLA is doing good in the industry, outperforming 66.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.49
Quick Ratio 6.49
PVLA Yearly Current Assets VS Current LiabilitesPVLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • PVLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.36%, which is quite impressive.
  • The Revenue for PVLA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)73.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.97%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 28.77% on average over the next years. This is a very strong growth
  • PVLA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 603.41% yearly.
EPS Next Y-17.14%
EPS Next 2Y-14.82%
EPS Next 3Y-22.99%
EPS Next 5Y28.77%
Revenue Next Year-100%
Revenue Next 2Y34.65%
Revenue Next 3Y871.72%
Revenue Next 5Y603.41%

3.3 Evolution

PVLA Yearly Revenue VS EstimatesPVLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
PVLA Yearly EPS VS EstimatesPVLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 20 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • PVLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PVLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PVLA Price Earnings VS Forward Price EarningsPVLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PVLA Per share dataPVLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • PVLA's earnings are expected to decrease with -22.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.82%
EPS Next 3Y-22.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PVLA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PALVELLA THERAPEUTICS INC

NASDAQ:PVLA (2/27/2026, 9:28:40 PM)

After market: 135.02 0 (0%)

135.02

-13.32 (-8.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)03-30
Inst Owners64.74%
Inst Owner Change12.53%
Ins Owners16.63%
Ins Owner Change0%
Market Cap1.60B
Revenue(TTM)N/A
Net Income(TTM)-35.07M
Analysts84.55
Price Target194.31 (43.91%)
Short Float %16.73%
Short Ratio5.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.13%
Min EPS beat(2)-20.45%
Max EPS beat(2)-13.81%
EPS beat(4)1
Avg EPS beat(4)-76.9%
Min EPS beat(4)-313.44%
Max EPS beat(4)40.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.32%
PT rev (3m)68.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.55%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 41.33
P/tB 41.33
EV/EBITDA N/A
EPS(TTM)-5.35
EYN/A
EPS(NY)-4.04
Fwd EYN/A
FCF(TTM)-1.92
FCFYN/A
OCF(TTM)-1.92
OCFYN/A
SpS0
BVpS3.27
TBVpS3.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.39%
ROE -90.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.19%
ROA(5y)-36.56%
ROE(3y)-79.34%
ROE(5y)-89.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.49
Quick Ratio 6.49
Altman-Z 30.98
F-Score3
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.97%
EPS Next Y-17.14%
EPS Next 2Y-14.82%
EPS Next 3Y-22.99%
EPS Next 5Y28.77%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y34.65%
Revenue Next 3Y871.72%
Revenue Next 5Y603.41%
EBIT growth 1Y-43.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-131.82%
EBIT Next 3Y-80.23%
EBIT Next 5Y50.12%
FCF growth 1Y51.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.68%
OCF growth 3YN/A
OCF growth 5YN/A

PALVELLA THERAPEUTICS INC / PVLA FAQ

What is the ChartMill fundamental rating of PALVELLA THERAPEUTICS INC (PVLA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PVLA.


What is the valuation status for PVLA stock?

ChartMill assigns a valuation rating of 0 / 10 to PALVELLA THERAPEUTICS INC (PVLA). This can be considered as Overvalued.


How profitable is PALVELLA THERAPEUTICS INC (PVLA) stock?

PALVELLA THERAPEUTICS INC (PVLA) has a profitability rating of 1 / 10.